-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The REFLECT study is a global, randomized, open-label, phase III clinical study that evaluates the efficacy of lenvatinib (Lenvatinib) versus sorafenib (sorafenib) in the first-line treatment of patients with unresectable hepatocellular carcinoma (uHCC)
.
Studies have shown that lenvatinib is not inferior to sorafenib
The REFLECT study is a global, randomized, open-label, phase III clinical study that evaluates the efficacy of lenvatinib (Lenvatinib) versus sorafenib (sorafenib) in the first-line treatment of patients with unresectable hepatocellular carcinoma (uHCC)
The study only included patients with ALBI grade 1 or 2 and CPS grade 5 or 6 who received lenvatinib or sorafenib
.
The CPS score was calculated using five indicators: serum bilirubin, serum albumin, ascites, encephalopathy, and INR
The study only included patients with ALBI grade 1 or 2 and CPS grade 5 or 6 who received lenvatinib or sorafenib
The median OS of ALBI level 1 patients receiving lenvatinib and sorafenib was 17.
OS
OSAmong patients who received follow-up anti-tumor therapy after lenvatinib treatment, the median OS of ALBI level 1 (n = 158) patients was 20.
9 months (95% CI: 17.
6–25.
9), and ALBI level 2 (n = 46) The patient’s median OS was 15.
1 months (95% CI: 12.
2–20.
8; HR 0.
643, 95% CI: 0.
440–0.
938)
.
9 months (95% CI: 17.
6–25.
9), and ALBI level 2 (n = 46) The patient’s median OS was 15.
1 months (95% CI: 12.
2–20.
8; HR 0.
643, 95% CI: 0.
440–0.
938)
.
The median PFS of ALBI level 1 patients receiving lenvatinib and sorafenib were 7.
4 months (95% CI: 7.
2–9.
1) and 3.
6 months (95% CI: 3.
6–4.
1), respectively; ALBI level 2 The median PFS of patients receiving lenvatinib and sorafenib was 5.
5 months (95% CI: 3.
6–7.
4) and 3.
5 months (95% CI: 1.
9–3.
7), respectively
.
In patients with CPS 5 points, the median PFS of receiving lenvatinib and sorafenib were 7.
The median PFS of ALBI level 1 patients receiving lenvatinib and sorafenib were 7.
PFS
PFSIn lenvatinib-treated patients, the ORRs of ALBI grade 1 and 2 patients were 45.
0% and 32.
3%, respectively; the ORRs of CPS 5 points and 6 points were 42.
9% and 33.
6%, respectively
.
In patients treated with sorafenib, the ORRs of ALBI grade 1 and 2 patients were 13.
In lenvatinib-treated patients, the ORRs of ALBI grade 1 and 2 patients were 45.
Efficacy evaluation
Efficacy evaluation Efficacy evaluationIn patients treated with lenvatinib, the proportions of ALBI grade 1 and grade 2 patients with ≥ grade 3 treatment-related adverse events (TEAE) were 69.
5% and 86.
1%, respectively; while those with CPS scores 5 and 6 were 71.
6% and 86.
1%, respectively.
86.
0%
.
Among patients treated with sorafenib, the proportions of ALBI grade 1 and grade 2 patients with ≥ grade 3 treatment-related adverse events (TEAE) were 62.
In patients treated with lenvatinib, the proportions of ALBI grade 1 and grade 2 patients with ≥ grade 3 treatment-related adverse events (TEAE) were 69.
5% and 86.
1%, respectively; while those with CPS scores 5 and 6 were 71.
6% and 86.
1%, respectively.
86.
0%
.
Among patients treated with sorafenib, the proportions of ALBI grade 1 and grade 2 patients with ≥ grade 3 treatment-related adverse events (TEAE) were 62.
1% and 77.
6%, respectively; while those with CPS scores 5 and 6 were 63.
2% and 63.
2%, respectively.
76.
3%
.
Treatment adverse events
Treatment adverse eventsIn summary, when patients with unresectable hepatocellular carcinoma are treated with lenvatinib or sorafenib, a better baseline liver function (such as ALBI grade or CPS score) may be a prognostic indicator of better survival
.
.
When patients with unresectable hepatocellular carcinoma are treated with lenvatinib or sorafenib, a good baseline liver function (such as ALBI grade or CPS score) may be a prognostic indicator of better survival
.
When patients with unresectable hepatocellular carcinoma are treated with lenvatinib or sorafenib, a good baseline liver function (such as ALBI grade or CPS score) may be a prognostic indicator of better survival
.
Original source:
Original source:Arndt Vogel, Catherine Frenette, Max Sung, et al.
Baseline Liver Function and Subsequent Outcomes in the Phase 3 REFLECT Study of Patients with Unresectable Hepatocellular Carcinoma.
Liver Cancer.
DOI: 10.
1159/000516490.
Published online: July 15, 2021
Arndt Vogel, Catherine Frenette, Max Sung, et al Baseline Liver Function and Subsequent Outcomes in the Phase 3 REFLECT Study of Patients with Unresectable Hepatocellular Carcinoma Liver Cancer DOI:.
.
10.
1159 / 000516490 Published online:.
July 15, 2021 in this message